TY - JOUR
T1 - Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology
AU - Shir, Dror
AU - Graff-Radford, Jonathan
AU - Hofrenning, Ekaterina I.
AU - Lesnick, Timothy G.
AU - Przybelski, Scott A.
AU - Lowe, Val J.
AU - Knopman, David S
AU - Petersen, Ronald C.
AU - Jack, Clifford R Jr.
AU - Vemuri, Prashanthi
AU - Algeciras-Schimnich, Alicia
AU - Campbell, Michelle R.
AU - Stricker, Nikki H.
AU - Mielke, Michelle M
N1 - Funding Information:
We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV‐1451 precursor, chemistry production advice and oversight, and FDA regulatory cross‐filing permission and documentation needed for this work. This study was supported by funding from the National Institutes of Health (RF1 AG069052‐01A1, U01 AG006786, R37 AG011378, R01 041851, R01 NS097495, and P30 AG062677) and the GHR Foundation. This study was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01 AG034676. The funding source had no role in study design, collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.
Funding Information:
We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. This study was supported by funding from the National Institutes of Health (RF1 AG069052-01A1, U01 AG006786, R37 AG011378, R01 041851, R01 NS097495, and P30 AG062677) and the GHR Foundation. This study was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01 AG034676. The funding source had no role in study design, collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.
Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: Plasma glial fibrillary acidic protein (GFAP) may be associated with amyloid burden, neurodegeneration, and stroke but its specificity for Alzheimer's disease (AD) in the general population is unclear. We examined associations of plasma GFAP with amyloid and tau positron emission tomography (PET), cortical thickness, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs). Methods: The study included 200 individuals from the Mayo Clinic Study of Aging who underwent amyloid and tau PET and magnetic resonance imaging and had plasma GFAP concurrently assayed; multiple linear regression and hurdle model analyses were used to investigate associations controlling for age and sex. Results: GFAP was associated with amyloid and tau PET in multivariable models. After adjusting for amyloid, the association with tau PET was no longer significant. GFAP was associated with cortical thickness, WMH, and lobar CMBs only among those who were amyloid-positive. Discussion: This cross-sectional analysis demonstrates the utility of GFAP as a plasma biomarker for AD-related pathologies.
AB - Introduction: Plasma glial fibrillary acidic protein (GFAP) may be associated with amyloid burden, neurodegeneration, and stroke but its specificity for Alzheimer's disease (AD) in the general population is unclear. We examined associations of plasma GFAP with amyloid and tau positron emission tomography (PET), cortical thickness, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs). Methods: The study included 200 individuals from the Mayo Clinic Study of Aging who underwent amyloid and tau PET and magnetic resonance imaging and had plasma GFAP concurrently assayed; multiple linear regression and hurdle model analyses were used to investigate associations controlling for age and sex. Results: GFAP was associated with amyloid and tau PET in multivariable models. After adjusting for amyloid, the association with tau PET was no longer significant. GFAP was associated with cortical thickness, WMH, and lobar CMBs only among those who were amyloid-positive. Discussion: This cross-sectional analysis demonstrates the utility of GFAP as a plasma biomarker for AD-related pathologies.
KW - Alzheimer's disease
KW - amyloid pathology astrogliosis
KW - blood-based biomarkers
KW - plasma glial fibrillary acidic protein
UR - http://www.scopus.com/inward/record.url?scp=85134900631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134900631&partnerID=8YFLogxK
U2 - 10.1002/dad2.12291
DO - 10.1002/dad2.12291
M3 - Article
AN - SCOPUS:85134900631
VL - 14
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
SN - 2352-8729
IS - 1
M1 - e12291
ER -